Premium
Anti‐tumour necrosis factor‐α treatment for perianal Crohn's disease in Australia
Author(s) -
Burger Daniel C,
Lawrance Ian C,
Bampton Peter A,
Prosser Ruth,
Croft Anthony,
Gilshenan Kristen,
RadfordSmith Graham L,
Florin Timothy H
Publication year - 2010
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.2010.tb03557.x
Subject(s) - medicine , crohn's disease , inflammatory bowel disease , disease , necrosis , tumor necrosis factor alpha , retrospective cohort study , crohn disease , surgery , gastroenterology
Objective: To examine the prevalence of perianal Crohn's disease (PCD) and the eligibility of PCD patients to access anti‐tumour necrosis factor‐alpha (anti‐TNFα) treatment under current Australian Pharmaceutical Benefits Scheme (PBS) guidelines. Design, setting and participants: A retrospective study of patients with Crohn's disease (CD) and PCD attending four large adult inflammatory bowel disease (IBD) centres in Australia between January 2004 and May 2008. Patients for whom anti‐TNFα therapy was clinically indicated were assessed to determine whether they satisfied PBS criteria for subsidised medication. Main outcome measures: Prevalence of CD and PCD in patients attending different IBD centres; eligibility of PCD patients for PBS‐subsidised anti‐TNFα medication. Results: Data were available on 3589 patients, representing about 6% of all patients with IBD in Australia. Of the 1815 patients with CD, 310 (17%) had PCD. Anti‐TNFα therapy was deemed clinically indicated for 166 patients with PCD (54%), of whom 49 (30%) did not qualify for PBS‐funded therapy. Conclusion: Thirty per cent of patients with clinically significant PCD currently do not have access to PBS‐subsidised optimal medical treatment. We believe that PBS criteria should be extended to include this subgroup of IBD patients.